Oxford Nanopore And A.D.A.M. Innovations Announce International Collaboration To Accelerate Advanced Genomic Medicine In Japan

OXFORD, England & TOKYO, March 18 (Bernama) -- Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co.), one of Japan’s leading genetic testing companies, today announce an international collaboration to develop and deploy advanced genomic sequencing and medicine applications based on comprehensive, nanopore sequencing in Japan.

In its initial phase, the collaboration has the potential to establish Oxford Nanopore’s information-rich, real-time sequencing technology across A.D.A.M. Innovations’ advanced genetic testing portfolio, enabling rapid and precise genomic testing across multiple disease areas. The goal of the collaboration is to introduce new clinical workflows under Japan-specific validation standards to support scalable sequencing of DNA fragments of any length for various conditions and diseases. Sequencing that captures complete genomic information will expand testing accuracy beyond what can be achieved through existing technologies.